This guide explains what the evidence shows and how to make informed decisions about your sleep support
For some patients, particularly those with specific comorbidities or medication combinations, a provider may recommend semaglutide as the more clinically appropriate choice
Mild flushing or warmth shortly after dosing
however, all four participants with SAEs were in the placebo group, with the participant with SUSAR in the semaglutide group
Clin Gastroenterol Hepatol 2025;23:739-47.ArticlePubMed 22
SURMOUNT-1 Trial (72-Week Duration, 2,539 Participants): Average weight loss with 15 mg: 20.9% of body weight Participants losing 5%: 91% Participants losing 10%: 82% Participants losing 20%: 57% SURMOUNT-2 Trial (People with Type 2 Diabetes): Average weight loss with 15 mg: 15.7% A1C reduction: 2.0 percentage points Source: Jastreboff AM, et al